Oyster Point Pharma, Inc
700 Alexander Park Drive Suite 301
Princeton, NJ 08540
United States
Tel: 609-382-9032
Website: http://ww.oysterpointrx.com/
About Oyster Point Pharma, Inc
Oyster Point is a clinical stage pharmaceutical company leveraging neuroscience to discover, develop and commercialize novel therapies to treat diseases with high unmet needs. The company’s initial focus is to develop innovative therapeutics to treat the signs and symptoms of Dry Eye Disease (DED) by stimulating the Trigeminal Parasympathetic Pathway (TPP) to activate the glands responsible for tear film production. The parasympathetic nervous system (PNS) is part of the involuntary nervous system responsible for regulating homeostasis, the “rest and digest” system, and is an important pathway for basal tear film production. Oyster Point Pharma is leveraging a class of receptors called nicotinic acetylcholine receptors (nAChRs) which are located on the trigeminal nerve, accessible within the nose, to stimulate tear film production in patients with Dry Eye Disease (DED).
Oyster Point Pharma, named after the Oyster Point waterfront on San Francisco Bay, was founded in 2015 and is headquartered in Princeton, New Jersey.
107 articles about Oyster Point Pharma, Inc
-
Oyster Point Pharma to Present New Clinical Data at the American Society of Cataract and Refractive Surgery (ASCRS) 2022
4/19/2022
Oyster Point Pharma, Inc. (Nasdaq: OYST), a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of first-in-class pharmaceutical therapies to treat ophthalmic diseases, today announced the presentation of data analyses at the American Society of Cataract and Refractive Surgery (ASCRS), being held on April 22-26.
-
Biopharma and life sciences companies continue to strengthen their executive teams and boards with this week’s Movers & Shakers.
-
Oyster Point Pharma Announces Retirement of William J. Link From Board of Directors
3/17/2022
Oyster Point Pharma, Inc. today announced that William J. Link, Ph.D., is retiring from Oyster Point’s Board of Directors, effective as of March 17, 2022.
-
Oyster Point Pharma to Participate in the Cowen 42nd Annual Health Care ConferenceConference Call and Webcast Scheduled for March 7, 2022, 10:30 A.M. ET
3/1/2022
Oyster Point Pharma, Inc. announced that the Company will participate virtually in the Cowen 42nd Annual Health Care Conference on Monday, March 7, 2022 at 10:30 a.m. ET.
-
Oyster Point Pharma Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Business Highlights
2/24/2022
Oyster Point Pharma, Inc. announced its financial results for the fourth quarter and full year ended December 31, 2021 and provided an overview of recent business highlights.
-
Oyster Point Pharma Announces TYRVAYA™ Nasal Spray Now Covered by Express Scripts
2/22/2022
Oyster Point Pharma, Inc. (Nasdaq: OYST), ("Oyster Point Pharma", or "the Company"), today announced TYRVAYATM Nasal Spray’s placement on the Express Scripts National Preferred, Basic, and High Performance Formularies, which collectively makes up an estimated 26 million lives, effective February 19, 2022.
-
Oyster Point Pharma To Report Fourth Quarter And Full Year 2021 Financial Results On February 24, 2022Conference Call and Webcast Scheduled for February 24, 2022, 4:30 p.m. ET
2/16/2022
Oyster Point Pharma, Inc. (Nasdaq: OYST), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ophthalmic diseases, today announced that it will report fourth quarter and full year 2021 financial results on Thursday, February 24, 2022, after the market close.
-
Oyster Point Pharma, Inc., Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
1/4/2022
Oyster Point Pharma, Inc. today announced that the Compensation Committee of its Board of Directors granted inducement non-qualified stock options to purchase an aggregate of 90,800 shares of common stock to seven new employees.
-
Oyster Point Pharma to Present at Upcoming Investor Conferences in January 2022
12/21/2021
Oyster Point Pharma, Inc. (Nasdaq: OYST), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ophthalmic diseases, today announced that the Company will participate virtually in the following upcoming investor conferences.
-
Oyster Point Pharma Announces Addition To Nasdaq Biotechnology Index
12/15/2021
Oyster Point Pharma, Inc. today announced that Oyster Point Pharma will be added to the Nasdaq Biotechnology Index (Nasdaq: NBI), which will become effective prior to market open on Monday, December 20.
-
Oyster Point Pharma to Participate in the Piper Sandler 33rd Annual Healthcare Conference
11/30/2021
Oyster Point Pharma, Inc. (Nasdaq: OYST), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ophthalmic diseases, today announced that the Company will participate virtually in the Piper Sandler 33rd Annual Healthcare Conference on Thursday, December 2, 2021.
-
Oyster Point Pharma Announces Expansion of Executive Leadership Team to Support Commercialization of Tyrvaya™ (varenicline solution) Nasal Spray for the Signs and Symptoms of Dry Eye Disease
11/24/2021
Oyster Point Pharma, Inc. today announced the promotion of Barry Rosenfeld, JD as General Counsel, and Raegan A. McClain, JD, LLM, CCEP as Chief Compliance offer, both of whom will join the executive leadership team.
-
Oyster Point Pharma Announces Publication in Ophthalmology of ONSET-2 Phase 3 Data on TYRVAYAᵀᴹ (varenicline solution) Nasal Spray
11/15/2021
Oyster Point Pharma, Inc. (Nasdaq: OYST), ("Oyster Point Pharma" or "the Company") today announced that results from the multicenter, randomized, double-masked, vehicle-controlled Phase 3 clinical trial (The ONSET-2 study) of TYRVAYATM Nasal Spray (varenicline solution) have been published in Ophthalmology.
-
Oyster Point Pharma to Present Data at the American Academy of Ophthalmology Annual Meeting 2021
11/9/2021
Oyster Point Pharma, Inc. today announced multiple scientific presentations at the American Academy of Ophthalmology (AAO) Annual Meeting 2021 being held in New Orleans, LA November 12th – 15th , 2021.
-
Oyster Point Pharma Reports Third Quarter 2021 Financial Results and Recent Business Highlights
11/4/2021
Oyster Point Pharma, Inc., a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ophthalmic diseases, announced its financial results for the third quarter of 2021, and provided an overview of recent business highlights.
-
Oyster Point Pharma Announces Patient Savings Program Where Eligible Patients Can Pay as Little as $0 for TYRVAYA™ (varenicline solution) Nasal Spray for the Treatment of The Signs and Symptoms of Dry Eye Disease
11/4/2021
Oyster Point Pharma, Inc., announced it has launched a patient support program called TEAMTyrvaya™ where eligible1 patients can pay as little as $0 for TYRVAYA™ Nasal Spray 0.03 mg.
-
Oyster Point Pharma’s TYRVAYA™ (varenicline solution) Nasal Spray is Now Available at U.S. Regional Wholesalers for Distribution to Pharmacies for the Treatment of the Signs and Symptoms of Dry Eye Disease
11/3/2021
Oyster Point Pharma, Inc. (Nasdaq: OYST), today announced that TYRVAYA™ (varenicline solution) Nasal Spray 0.03 mg is now available at U.S. regional wholesalers for distribution to pharmacies. The U.S. Food and Drug Administration (FDA), approved TYRVAYA Nasal Spray for the treatment of the signs and symptoms of dry eye disease on October 15, 2021.
-
Oyster Point Pharma to Present Data at the American Academy of Optometry Annual Meeting 2021
11/2/2021
Oyster Point Pharma, Inc., a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ophthalmic diseases, announced multiple scientific presentations at the American Academy of Optometry Annual Meeting 2021 being held in Boston, MA November 3 - 6, 2021.
-
Oyster Point Pharma to Report Third Quarter 2021 Financial Results on November 4, 2021Conference Call and Webcast Scheduled for November 4, 2021, 4:30 p.m. Eastern Time
10/28/2021
Oyster Point Pharma, Inc. today announced that it will report third quarter 2021 financial results on Thursday, November 4, 2021, after the market close.
-
Oyster Point Pharma Announces FDA Approval of TYRVAYA™ (varenicline solution) Nasal Spray for the Treatment of the Signs and Symptoms of Dry Eye Disease
10/18/2021
Oyster Point Pharma, Inc., announced that the U.S. Food and Drug Administration has approved TYRVAYA™ Nasal Spray 0.03 mg for the treatment of the signs and symptoms of dry eye disease.